CD4 and neoplasm: Combination therapy resulted in a significant increase in the frequency of CD4+ T cells and M1 macrophages, which are associated with antitumor responses, while there was a decrease in pro‐tumor immune cells, such as MDSCs and M2 macrophages [28]